Future direction of synthetic polyanions (pyran copolymer)
- PMID: 365328
Future direction of synthetic polyanions (pyran copolymer)
Abstract
Pyran copolymer (maleic anhydride-divinyl ether) has consistently reproducible molecular weight-related biologic effects associated with toxic, immunologic antitumor, and antiviral effects. Fortunately, the antitumor action occurs with the least toxic lower molecular weight fraction. Immunoadjuvant effects with this fraction would be critical to its development. Studies of polymers should include evaluation of effects on splenomegaly, splenic esterase changes, lipolysis, reverse transcriptase, nucleases, calcium flux, cyclic nucleotides, and complement and clotting elements.
Similar articles
-
Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether (MVE) polyanions.Cancer Treat Rep. 1978 Nov;62(11):1797-803. Cancer Treat Rep. 1978. PMID: 103618
-
Effect of maleic anhydride-divinyl ether copolymers on experimental M109 metastases and macrophage tumoricidal function.Cancer Treat Rep. 1978 Nov;62(11):1817-22. Cancer Treat Rep. 1978. PMID: 728899
-
Mobilization of murine hemopoietic stem cells (HSC) by Pyran Copolymer.Exp Hematol. 1979;7 Suppl 5:116-24. Exp Hematol. 1979. PMID: 263238
-
[Antitumor activity of polyanion and its application for drug delivery system of antitumor drugs].Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):542-7. Gan To Kagaku Ryoho. 1990. PMID: 2138872 Review. Japanese.
-
The biological activity of the synthetic polyanion, pyran copolymer (diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: clinical and laboratory effects of these agents as modulators of host resistance.Pharmacol Ther. 1981;15(1):1-44. doi: 10.1016/0163-7258(81)90014-0. Pharmacol Ther. 1981. PMID: 7038712 Review. No abstract available.
Cited by
-
Studies on the antitumor activities of pyrimidinone-interferon inducers. Part 2. Potentiation of antitumor resistance mechanisms.Clin Exp Metastasis. 1983 Jul-Sep;1(3):213-22. doi: 10.1007/BF00736405. Clin Exp Metastasis. 1983. PMID: 6336272
-
Phase I trial of a 5-day course of carbetimer.Invest New Drugs. 1990;8 Suppl 1:S41-9. doi: 10.1007/BF00171983. Invest New Drugs. 1990. PMID: 2380016